{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:12:42Z","timestamp":1771863162025,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100016204","name":"Ministry of Higher Education, Science, Research and Innovation, Thailand","doi-asserted-by":"publisher","award":["Fundamental Fund 2025 (270\/2567)"],"award-info":[{"award-number":["Fundamental Fund 2025 (270\/2567)"]}],"id":[{"id":"10.13039\/501100016204","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13318-025-00980-1","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:37:39Z","timestamp":1767433059000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose Optimization of Piperacillin for Pseudomonas aeruginosa Infection in Febrile Neutropenic Pediatric Patients"],"prefix":"10.1007","volume":"51","author":[{"given":"Chanon","family":"Supapon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirima","family":"Sitaruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sutthiporn","family":"Pattharachayakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preecha","family":"Montakantikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6169-0039","authenticated-orcid":false,"given":"Apinya","family":"Boonpeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"980_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/children8121086","author":"F Cennamo","year":"2021","unstructured":"Cennamo F, Masetti R, Largo P, Argentiero A, Pession A, Esposito S. Update on febrile neutropenia in pediatric oncological patients undergoing chemotherapy. Children. 2021. https:\/\/doi.org\/10.3390\/children8121086.","journal-title":"Children"},{"key":"980_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081800","author":"E Boeriu","year":"2022","unstructured":"Boeriu E, Borda A, Vulcanescu DD, Sarbu V, Arghirescu ST, Ciorica O, et al. Diagnosis and management of febrile neutropenia in pediatric oncology patients-a systematic review. Diagnostics. 2022. https:\/\/doi.org\/10.3390\/diagnostics12081800.","journal-title":"Diagnostics"},{"issue":"9","key":"980_CR3","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1200\/jco.22.02224","volume":"41","author":"T Lehrnbecher","year":"2023","unstructured":"Lehrnbecher T, Robinson PD, Ammann RA, Fisher B, Patel P, Phillips R, et al. Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update. J Clin Oncol. 2023;41(9):1774\u201385. https:\/\/doi.org\/10.1200\/jco.22.02224.","journal-title":"J Clin Oncol"},{"key":"980_CR4","doi-asserted-by":"publisher","DOI":"10.1086\/516284","author":"WA Craig","year":"1998","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998. https:\/\/doi.org\/10.1086\/516284.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"980_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127\u201353. https:\/\/doi.org\/10.1007\/s00134-020-06050-1.","journal-title":"Intensive Care Med"},{"issue":"10","key":"980_CR6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/jac\/dkad223","volume":"78","author":"R Pai Mangalore","year":"2023","unstructured":"Pai Mangalore R, Peel TN, Udy AA, Peleg AY. The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting. J Antimicrob Chemother. 2023;78(10):2395\u2013405. https:\/\/doi.org\/10.1093\/jac\/dkad223.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"980_CR7","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","volume":"72","author":"S Imani","year":"2017","unstructured":"Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72(10):2891\u20137. https:\/\/doi.org\/10.1093\/jac\/dkx209.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"980_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jac\/dkac416","volume":"78","author":"S Tang Girdwood","year":"2023","unstructured":"Tang Girdwood S, Hasson D, Caldwell JT, Slagle C, Dong S, Fei L, et al. Relationship between piperacillin concentrations, clinical factors and piperacillin\/tazobactam-associated acute kidney injury. J Antimicrob Chemother. 2023;78(2):478\u201387. https:\/\/doi.org\/10.1093\/jac\/dkac416.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"980_CR9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/cid\/cis210","volume":"54","author":"U Theuretzbacher","year":"2012","unstructured":"Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis. 2012;54(12):1785\u201392. https:\/\/doi.org\/10.1093\/cid\/cis210.","journal-title":"Clin Infect Dis"},{"key":"980_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101182","author":"M Gijsen","year":"2021","unstructured":"Gijsen M, Vlasselaers D, Spriet I, Allegaert K. Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine. Antibiotics. 2021. https:\/\/doi.org\/10.3390\/antibiotics10101182.","journal-title":"Antibiotics"},{"key":"980_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11040458","author":"G Loeuille","year":"2022","unstructured":"Loeuille G, D\u2019Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, et al. Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy. Antibiotics (Basel). 2022. https:\/\/doi.org\/10.3390\/antibiotics11040458.","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"980_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/pbc.25287","volume":"62","author":"JJ Cies","year":"2015","unstructured":"Cies JJ, Jain J, Kuti JL. Population pharmacokinetics of the piperacillin component of piperacillin\/tazobactam in pediatric oncology patients with fever and neutropenia. Pediatr Blood Cancer. 2015;62(3):477\u201382. https:\/\/doi.org\/10.1002\/pbc.25287.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"980_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27654","volume":"66","author":"SF Maarbjerg","year":"2019","unstructured":"Maarbjerg SF, Thorsted A, Kristoffersson A, Friberg LE, Nielsen EI, Wang M, et al. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: can we optimize our dosing strategy? Pediatr Blood Cancer. 2019;66(6):e27654. https:\/\/doi.org\/10.1002\/pbc.27654.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"980_CR14","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/jac\/dkz270","volume":"74","author":"A Thorsted","year":"2019","unstructured":"Thorsted A, Kristoffersson AN, Maarbjerg SF, Schr\u00f8der H, Wang M, Brock B, et al. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. J Antimicrob Chemother. 2019;74(10):2984\u201393. https:\/\/doi.org\/10.1093\/jac\/dkz270.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"980_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1585","volume":"5","author":"SF Maarbjerg","year":"2022","unstructured":"Maarbjerg SF, Thorsted A, Friberg LE, Nielsen EI, Wang M, Schr\u00f8der H, et al. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever. Cancer Rep (Hoboken). 2022;5(10):e1585. https:\/\/doi.org\/10.1002\/cnr2.1585.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"6","key":"980_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciu402","volume":"59","author":"NJ Rhodes","year":"2014","unstructured":"Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. Clin Infect Dis. 2014;59(6):905\u20137. https:\/\/doi.org\/10.1093\/cid\/ciu402.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"980_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ijantimicag.2015.01.007","volume":"45","author":"JJ De Waele","year":"2015","unstructured":"De Waele JJ, Lipman J, Carlier M, Roberts JA. Subtleties in practical application of prolonged infusion of \u03b2-lactam antibiotics. Int J Antimicrob Agents. 2015;45(5):461\u20133. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.01.007.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"980_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106113","volume":"56","author":"IK Delattre","year":"2020","unstructured":"Delattre IK, Hites M, Laterre PF, Dugernier T, Spapen H, Wallemacq PE, et al. What is the optimal loading dose of broad-spectrum \u03b2-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling. Int J Antimicrob Agents. 2020;56(4):106113. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106113.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"980_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","volume":"43","author":"LT Hong","year":"2023","unstructured":"Hong LT, Downes KJ, FakhriRavari A, Abdul-Mutakabbir JC, Kuti JL, Jorgensen S, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023;43(8):740\u201377. https:\/\/doi.org\/10.1002\/phar.2842.","journal-title":"Pharmacotherapy"},{"key":"980_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06506-y","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021. https:\/\/doi.org\/10.1007\/s00134-021-06506-y.","journal-title":"Intensive Care Med"},{"issue":"2","key":"980_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40262-018-0682-1","volume":"58","author":"A B\u00e9ranger","year":"2019","unstructured":"B\u00e9ranger A, Benaboud S, Urien S, Moulin F, Bille E, Lesage F, et al. Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance. Clin Pharmacokinet. 2019;58(2):223\u201333. https:\/\/doi.org\/10.1007\/s40262-018-0682-1.","journal-title":"Clin Pharmacokinet"},{"key":"980_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00311-17","author":"FB Sime","year":"2017","unstructured":"Sime FB, Hahn U, Warner MS, Tiong IS, Roberts MS, Lipman J, et al. Using population pharmacokinetic modeling and Monte Carlo simulations to determine whether standard doses of piperacillin in piperacillin-tazobactam regimens are adequate for the management of febrile neutropenia. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.00311-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"980_CR23","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1128\/aac.38.12.2817","volume":"38","author":"MD Reed","year":"1994","unstructured":"Reed MD, Goldfarb J, Yamashita TS, Lemon E, Blumer JL. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother. 1994;38(12):2817\u201326. https:\/\/doi.org\/10.1128\/aac.38.12.2817.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00980-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00980-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00980-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:38:46Z","timestamp":1771861126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00980-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00980-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study did not involve the collection of new clinical data. All data used in the analysis were derived from previously published population PK parameters by Thorsted et al. [\n                      \n                      ]. No new datasets were generated. The simulation parameters, dosing scenarios, and target attainment analyses are fully described in the Methods section of the manuscript. Further details are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable. This study involved model-based simulations using previously published pharmacokinetic parameters without involving new patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable. This study did not involve identifiable individual data or images.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The simulations were performed using standard commercial software (Microsoft Excel and Oracle Crystal Ball). No custom code was developed or used in this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"C.S. led the study conceptualization, conducted data extraction, performed simulation analyses, interpreted the results, and drafted the original manuscript. S.S. contributed to the conceptual framework, designed the methodology, validated the model, analyzed data, and participated in interpreting the findings and refining the manuscript. S.P. and P.M. were responsible for data verification, carried out statistical analyses, and contributed to interpreting the results and reviewing the manuscript. A.B. provided overall supervision and conceptual guidance, supported model validation and data interpretation, and coordinated the manuscript preparation and critical revisions. All authors reviewed and approved the final manuscript and take full responsibility for the integrity and accuracy of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}